InvestorWire NewsRoom

Article

Lexaria Bioscience Corp. (NASDAQ: LEXX) to Address Advances in its Bioavailability Technology DehydraTECH(TM) at Wainwright Life Sciences Conference
September 9, 2021

Lexaria Bioscience Corp. (NASDAQ: LEXX) to Address Advances in its Bioavailability Technology DehydraTECH(TM) at Wainwright Life Sciences Conference

  • Drug delivery technology innovator Lexaria Bioscience is celebrating the positive outcomes of clinical testing of its trademarked DehydraTECH platform for reducing the blood stream delivery time of anti-virals, NSAIDS and potential hypertension treatments
  • Lexaria will participate in H.C. Wainwright’s annual Global Investor Conference this month to help bring further attention to its successes
  • The DehydraTECH technology enhances the delivery of pharmaceuticals that can be administered orally, and testing has shown no adverse chemical compounds have been created in the process
  • The COVID-19 pandemic has raised the profile of the anti-viral medication market, enhancing the opportunities for Lexaria’s revenue stream

As life sciences technology innovator Lexaria Bioscience (NASDAQ: LEXX) takes a leap forward in R&D programs demonstrating the effectiveness of its trademarked oral substance delivery platform, the company is preparing to join other participants in the 23rd annual Global Investor Conference hosted by full-service investment bank H.C. Wainwright & Co.

The investor conference scheduled Sept. 13-15 will be a hybrid online and in-person gathering of companies enjoying opportunities for platform presentations, one-on-one meetings with investors, and networking with other attendees (https://ibn.fm/TiS8V). Lexaria’s CEO, Chris Bunka, will be making the company’s presentation, which will be available to attendees on Monday September 13th.  

Lexaria’s recent strides in developing and testing its oral delivery platform DehydraTECH include its successful 2021 antiviral drug program, which has produced data showing DehydraTECH can enhance antiviral drugs’ ability to reach the bloodstream so that they can safely and more effectively do what they are designed to accomplish. 

DehydraTECH processed substances such as pharmaceutical drugs enhance their bioavailability, and the clinical trials have also demonstrated that DehydraTECH does not alter nor degrade the drug molecules chemically as to create new molecular entities (“NMEs”) that would create new regulatory concerns for the finished products (https://ibn.fm/VWWld).

H.C. Wainwright has a history of leading investment transaction volumes ranked by market research service PlacementTracker. Wainwright has consistently placed first among investment banks for confidentially marketed public offerings, registered direct and private placement transactions, according to the analysts (https://ibn.fm/lG6DA).

The September event will include a panel discussion with former Food and Drug Administration Commissioner Scott Gottlieb (2017-2019), who is a member of the board of directors of drug maker Pfizer, Inc., and is preparing to roll out his long-awaited book, “Uncontrolled Spread: Why COVID-19 Crushed Us and How We Can Defeat the Next Pandemic,” this month. 

The antiviral medication market has gained particular attention during the ongoing COVID-19 pandemic, and Lexaria’s DehydraTECH is in a position to potentially bring in significant revenues in partnership with the antiviral medications as well as NSAIDs and products that target hypertension and alternative nicotine products — an opportunity the company has been mindful of. 

The potential for using DehydraTECH in conjunction with cannabidiol (“CBD”) to target hypertension is one of the sectors of Lexaria’s research gaining attention following the results of a recent study showing DehydraTECH-processed CBD generated a rapid and sustained drop in blood pressure among study participants (https://ibn.fm/AZQYS). 

“Lexaria was also pleased that its DehydraTECH-CBD was well tolerated by all subjects, with no serious adverse events or side effects observed or reported. Ingestion of the concentration-matched, generic CBD control, on the other hand, resulted in unwanted side effects in some of the volunteers,” the company’s news release states. “These findings corroborate what Lexaria has previously evidenced in other unrelated studies whereby human volunteers have also experienced reduced side effects with DehydraTECH-processed test articles compared to concentration-matched, generic controls.”

A second human clinical hypertension study of DehydraTECH’s capabilities is under way, and a third study is planned this year once the results of the first two studies are carefully evaluated and considered. 

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).